Literature DB >> 16028137

Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis.

William W Hope1, Peter A Warn, Andrew Sharp, Paul Reed, Brian Keevil, Arnold Louie, David W Denning, George L Drusano.   

Abstract

The strategy of combining antifungal drugs in a treatment regimen may improve the outcome of invasive candidiasis. Using a well-validated pharmacodynamic murine model of invasive candidiasis, we defined the effect of the combination of amphotericin B deoxycholate (AmB) and 5-fluorocytosine (5FC) by use of the Greco model of drug interaction. The combination was additive, meaning that the experimental effect did not deviate in a statistically significant manner from the null reference model (or additive surface) of the combined effect. From a clinical perspective, the addition of 5FC to a regimen of AmB may enable the near-maximum effect to be reached in circumstances in which the administration of a given dose of AmB alone produces a submaximum effect but an increase in the dose is not possible, because of dose-related toxicity. Our methods provide a way in which some of the complex issues surrounding antifungal combination treatment can be addressed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16028137     DOI: 10.1086/432069

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect.

Authors:  William W Hope; Peter A Warn; Andrew Sharp; Susan Howard; Miki Kasai; Arnold Louie; Thomas J Walsh; George L Drusano; David W Denning
Journal:  Antimicrob Agents Chemother       Date:  2006-09-05       Impact factor: 5.191

2.  Modeling the combination of amphotericin B, micafungin, and nikkomycin Z against Aspergillus fumigatus in vitro using a novel response surface paradigm.

Authors:  Yseult F Brun; Carly G Dennis; William R Greco; Ralph J Bernacki; Paula J Pera; Jennifer J Bushey; Richard C Youn; Donald B White; Brahm H Segal
Journal:  Antimicrob Agents Chemother       Date:  2007-02-26       Impact factor: 5.191

3.  Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis.

Authors:  William W Hope; George L Drusano; Caroline B Moore; Andrew Sharp; Arnold Louie; Thomas J Walsh; David W Denning; Peter A Warn
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

4.  Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing.

Authors:  William W Hope; Peter A Warn; Andrew Sharp; Paul Reed; Brian Keevil; Arnold Louie; Thomas J Walsh; David W Denning; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2007-08-06       Impact factor: 5.191

5.  Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis.

Authors:  Adam R Jeans; Susan J Howard; Zaid Al-Nakeeb; Joanne Goodwin; Lea Gregson; Peter A Warn; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2012-07-23       Impact factor: 5.191

6.  Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients.

Authors:  Lucy O'Connor; Joanne Livermore; Andrew D Sharp; Joanne Goodwin; Lea Gregson; Susan J Howard; Timothy W Felton; Julie A Schwartz; Michael N Neely; Thomas S Harrison; John R Perfect; William W Hope
Journal:  J Infect Dis       Date:  2013-04-18       Impact factor: 5.226

7.  Combination antifungal therapy involving amphotericin B, rapamycin and 5-fluorocytosine using PEG-phospholipid micelles.

Authors:  Ronak Vakil; Kayla Knilans; David Andes; Glen S Kwon
Journal:  Pharm Res       Date:  2008-04-16       Impact factor: 4.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.